FDA's Endocrinologic and Metabolic Drugs Advisory Committee
Executive Summary
Will discuss preclinical studies and efficacy criteria for anti- osteoposotic drugs at its next meeting, scheduled for May 7-8 in Conference Rooms D&E of FDA's Parklawn Building, Rockville, Md. at 8 a.m. each day.